Sho -ichi Yamagishi
Department of Internal Medicine Ill, Kurume University School of Medicine, Kurume, Japan
Kazuo Nakamura
Department of Internal Medicine Ill, Kurume University School of Medicine, Kurume, Japan
Yuko Jinnouchi
Department of Internal Medicine Ill, Kurume University School of Medicine, Kurume, Japan
Katsuhiko Takenaka
Department of Internal Medicine Ill, Kurume University School of Medicine, Kurume, Japan
Tsutomu Imaizumi
Department of Internal Medicine Ill, Kurume University School of Medicine, Kurume, Japan
ABSTRACT
Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of Advanced Glycation End-products (AGEs) in vivo. There is a growing body of evidence that formation and accumulation of AGEs progress during normal aging and at an extremely accelerated rate under diabetes, thus being involved in the pathogenesis of various diseases such as diabetic vascular complications and neurodegenerative diseases. Recently, engagement of their receptor, RAGE, is shown to activate its down-stream signaling and subsequently evoke inflammatory responses in various types of cells. Therefore, inhibition of AGE formation or blockade of the RAGE signaling may be a promising target for therapeutic intervention in the AGE-RAGE-related devastating disorders. In this review, we discuss several types of blockers of the AGE-RAGE system and their therapeutic implications in diseases.
PDF References
How to cite this article
Sho -ichi Yamagishi, Kazuo Nakamura, Yuko Jinnouchi, Katsuhiko Takenaka and Tsutomu Imaizumi, 2005. Therapeutic Implications of Blockers of Advanced Glycation End Products (AGEs)-their Receptor (RAGE) System. International Journal of Pharmacology, 1: 203-209.
DOI: 10.3923/ijp.2005.203.209
URL: https://scialert.net/abstract/?doi=ijp.2005.203.209
DOI: 10.3923/ijp.2005.203.209
URL: https://scialert.net/abstract/?doi=ijp.2005.203.209
REFERENCES
- Vlassara, H., R. Bucala and L. Striker, 1994. Pathogenic effects of advanced glycosylation: Biochemical, biologic and clinical implications for diabetes and aging. Lab. Invest., 70: 138-151.
Direct Link - Brownlee, M., 1995. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med., 46: 223-234.
Direct Link - Kikuchi, S., K. Shinpo, A. Ogata, S. Tsuji, M. Takeuchi, Z. Makita and K. Tashiro, 2002. Detection of N-(carboxymethyl)lysine (CML) and non-CML advanced glycation end products in the anterior horn of amyotrophic lateral sclerosis spinal cord. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 3: 63-68.
- Brownlee, M., H. Vlassara, A. Kooney, P. Ulrich and A. Cerami, 1986. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 232: 1629-1632.
CrossRefPubMedDirect Link - Frank, R.N., R. Amin, A. Kennedy and T.C. Hohman, 1997. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch. Ophthalmol., 115: 1036-1047.
PubMed - Yamauchi, A., I. Takei, Z. Makita, S. Nakamoto and N. Ohashi et al., 1997. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albumin excretion, mesangial expansion and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res. Clin. Pract., 34: 127-133.
- Tanaka, Y., H. Iwamoto and T. Onuma, 1997. Inhibitory effect of metformin on formation of advanced glycation end products. Curr. Ther. Res., 58: 693-697.
CrossRef - Voziyan, P.A., T.O. Metz, J.W. Baynes and B.G. Hudson, 2002. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem., 277: 3397-3403.
CrossRefDirect Link - Thomas, O.M., L.A. Nathan, R.T. Suzanne and W.B. John, 2003. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys., 419: 41-49.
Direct Link - Stitt, A., T.A. Gardiner, N.L. Alderson, P. Canning and N. Frizzell et al., 2002. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes, 51: 2826-2832.
Direct Link - Yamamoto, Y., I. Kato, T. Doi, H. Yonekura and S. Ohashi et al., 2001. Development and prevention of advanced diabetic nephropathy in rage-overexpressing mice. J. Clin. Invest., 108: 261-268.
CrossRefDirect Link - Saletu, B., H.V. Semlitsch, P. Anderer, F. Resch, O. Presslich and P. Schuster, 1989. Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese Psychophysiological Test-System (VPTS). Methods Find Exp. Clin. Pharmacol., 11: 43-55.
- Jerums, G., S. Panagiotopoulos, J. Forbes, T. Osicka and M. Cooper, 2003. Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease. Arch. Biochem. Biophys., 419: 55-62.
Direct Link - Inagaki, Y., S. Yamagishi, T. Okamoto, M. Takeuchi and S. Amano, 2003. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 46: 284-287.
- Bailey, C.J. and R.C. Turner, 1996. Metformin. N. Engl. J. Med., 334: 574-579.
CrossRefPubMedDirect Link